The BiliSeq molecular test developed at UPMC doubled detection sensitivity for bile duct cancer compared to standard pathology.
Key Details
- 1BiliSeq detected 82% of bile duct cancers vs. 44% with pathology alone in a six-year, multi-center study of over 2,000 patients.
- 2Combining BiliSeq with pathology increased detection up to 90% while minimizing false positives for benign disease.
- 3The test identifies actionable genetic mutations in about 20% of patients, informing care changes in nearly a third of those cases.
- 4BiliSeq maintains high performance in at-risk subgroups, detecting up to 86% of cancers in high-risk patients like those with PSC.
- 5Results have direct implications for diagnosis clarification and treatment—including transplant decisions—where imaging and standard biopsies often fail.
Why It Matters
This study demonstrates transformative potential for molecular diagnostics to support radiology and pathology in challenging cancer cases, reducing uncertainty for clinicians and patients. Enhanced diagnostic accuracy may lead to faster, more tailored interventions, especially in hard-to-assess biliary cancers.
Source
EurekAlert
Related News
•EurekAlert
New AI Method Removes Artifacts in Super-Resolution Fluorescence Microscopy
Researchers unveil Adaptive-SN2N, a self-supervised deep learning framework that suppresses background artifacts in super-resolution fluorescence microscopy images.
•EurekAlert
Micro-CT and AI Reveal Hidden Damage in Coral Skeletons
Researchers combined micro-CT imaging and deep learning to detect subtle disease-induced changes in coral skeletons with high accuracy.
•EurekAlert
Deep Learning AI Deciphers Hidden Self-Organization in Bacterial Colonies
Rice University researchers engineered an AI system to reveal subtle organizational patterns in bacterial communities using time-lapse microscopy data.